Pompe Disease Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Pompe Disease remains an active clinical development field. One-time and precision therapies are raising the efficacy ceiling, but durability, manufacturing, small-population evidence and long-term safety remain decisive constraints. The PatSnap evidence set used here contains 100 matched trial records and 84 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07700147 | Intervention not normalized | Not Applicable; Not yet recruiting | Nu Eyne Co. Ltd. | South Korea | Change in Best Corrected Visual Acuity (BCVA) Measured by ETDRS Letter Score (Baseline, Week 2, Week 6, Week 12, Week 16); Change in Contrast Sensitivity (Baseline, Week 2, Week 6, Week 12, Week 16) | 2027-12-09 |
| NCT07664930 | Intervention not normalized | Not Applicable; Recruiting | IRCCS National Neurological Institute C. Mondino Foundation | Italy | Motor latency (ms) (Baseline (at first available assessment, retrospective or prospective)); Compound muscle action potential (CMAP) amplitude (millivolts) (Baseline (at first available assessment, retrospective or prospective)) | 2029-02-28 |
| NCT07652814 | Avalglucosidase alfa | Phase 4; Active, not recruiting | Sponsor not listed | Netherlands | Incidence/occurrence of adverse events (From enrollment to the end of study duration at 5 years); The occurence of antibodies against avalglucosidase alfa (From enrollment to the end of study duration at 5 years) | 2028-03-09 |
| JPRN-jRCT2071260009 | Pegcetacoplan + Geographic Atrophy (Clearside) + Gambogic acid | Phase 3; 募集前 | Apellis Pharmaceuticals, Inc. | Japan | AMDに伴うGAを有する日本人被験者を対象に、pegcetacoplanをIVT投与したときの安全性及び忍容性を評価する ・TEAE（治験薬投与後に発現した有害事象）及び重篤なTEAEの発現率及び重症度; To assess the safety and tolerability of pegcetacoplan administered IVT in Japanese participants with GA secondary to AMD - incidence and severity of TEAEs (treatment-emergent adverse event) and serious TEAEs | 2028-05-31 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- Aro Biotherapeutics Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD) (Phase 1): the indexed record reports GYS1 mRNA knockdown(Week 10) = - 62.0 %.
- Update on FORTIS: A phase 1/2 open-label clinical trial on AT845 gene replacement therapy for late-onset Pompe disease (Phase 1/2): the indexed record reports 6MWD(48 weeks) = −0.19 % predicted ( −0.9 - 0.5).
- 90-month pulmonary function outcomes with cipaglucosidase alfa+miglustat in adults with Pompe disease in ATB200-02, an open-label phase I/II study (Phase 1/2): the indexed record reports ppFVC(month 60) = 5.0 % ( 8.07); -.
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Avalglucosidase alfa (Approved; M6PR x α-glucosidase), Pegcetacoplan (Approved; C3), Geographic Atrophy (Clearside) (Preclinical), Gambogic acid (Preclinical; HSP90 x Tubulin). Company & Deal Intelligence records identify sponsor context for Nu Eyne Co. Ltd., IRCCS National Neurological Institute C. Mondino Foundation, Apellis Pharmaceuticals, Inc. (APLS). Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Natural-history-aligned endpoints that remain interpretable in small heterogeneous cohorts.
- Long-term registries for durability, immunogenicity and delayed safety signals.
- Redosing, rescue and treatment-sequencing strategies after incomplete response.
- Access models that address diagnosis, manufacturing and global delivery.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Pompe Disease has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
